Overview
Browse spinoutsLegal name
AISENTIA LIMITED
Region
East of England
Registered address
Unknown
Insolvency history
No
Spinout
Active
LTD
Company profile
Aisentia Limited
AiSentia Improving Patient Journeys
Aisentia Limited is a UK company with status active founded in 2021 based in East of England.
CRN
13165345
Founded
2021
Age
5
Company events
Reference milestones and recent Companies House filing stream events.
3 events
12 Nov
2024
Capital Allotment Shares
CapitalSH01 | Transaction MzQ0MjgxNjU2MGFkaXF6a2N4
Published 12 Nov 2024 01:57
30 Sep
2024
Accounts With Accounts Type Small
Accounts Awaiting analysisAA | Transaction MzQzNzc1OTIzOWFkaXF6a2N4
Published 30 Sep 2024 02:16
28 Jan
2021
Incorporated
InceptionCompany registered at Companies House
Spinout profile
3 entries
Company description
AiSentia develops computerised tomography (CT) scanner technology which does not require the usage of radiographic contrast media.
AiSentia is a limited company that manufactures medical software as a device. Our product focus on applying artificial intelligence to computerised tomography imaging to extract higher order details that is otherwise not visualised by human eyes.
Project impact
We are at seed funding stage. Secured pre-seed investment from a Dutch venture builder (NLC health) and co-founder investment. Awarded non-dilutive funding from Innovate UK Smart Grant and SBRI NHS NET ZERO award.
AiSentia
2021
AiSentia
2021
AISENTIA LIMITED
2021
Public funding
2 awards
First funded
2022
Funded years
2022, 2023
Age at first award
1 years
Projects
2023
EU-Funded
Lead participant
NetZeroAICT Digital Contrast for Computerised Tomography Towards Climate Neutral and Sustainable Health Systems
1 Dec 2023 to 30 Nov 2027
Awarded
£492,073
Total cost £492,073
Computerised Tomography (CT) scan is one of the most common medical imaging performed in healthcare, Each year, 300 million CT scans are performed globally. Of which, around 180M include use of radiocontrast media (RCM). Contrast Enhanced CTs (CECT) create a significant environmental impact, namely: 42,000 tonnes of single use packaging, 900 Tonnes of sur...
2022
Collaborative R&D
Lead participant
AiSentia - The next generation of contrast-enhanced imaging in computerised tomography (CT)
1 Jun 2022 to 30 Nov 2023
Awarded
£349,602
Total cost £499,432
AiSentia is a spin-out from the University of Oxford consisting of a world-class team that delivers innovative healthcare solutions that champion patient care. AiSentia's aim is to develop next generation clinical imaging technologies using Artificial Intelligence (AI) to support clinical decision-making on blood vessels. The proprietary AI-driven softwar...
Product types
Collaborative R&D
EU-Funded